Search

Your search keyword '"Falkai, P."' showing total 63 results

Search Constraints

Start Over You searched for: Author "Falkai, P." Remove constraint Author: "Falkai, P." Topic antipsychotic agents Remove constraint Topic: antipsychotic agents
63 results on '"Falkai, P."'

Search Results

1. Somatic multicomorbidity and disability in patients with psychiatric disorders in comparison to the general population: a quasi-epidemiological investigation in 54,826 subjects from 40 countries (COMET-G study).

2. Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis.

3. Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia (The EARLY Trial): Protocol of a Randomized-Controlled Multicentric Trial.

4. Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trial.

5. Prevention of First-Episode Psychosis in People at Clinical High Risk: A Randomized Controlled, Multicentre Trial Comparing Cognitive-Behavioral Therapy and Clinical Management Plus Low-Dose Aripiprazole or Placebo (PREVENT).

7. The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post hoc analysis of three randomized, placebo-controlled trials.

8. Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review.

9. Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data.

10. The revised DGPPN and APA schizophrenia guidelines: Guideline quality and recommendations for long-term antipsychotic treatment.

11. Characteristics and definitions of ultra-treatment-resistant schizophrenia - A systematic review and meta-analysis.

12. Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis.

13. Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group.

14. Effects of Smoking Status on Remission and Metabolic and Cognitive Outcomes in Schizophrenia Patients Treated with Clozapine.

15. Schizophrenia.

16. Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment.

17. [Revised S3 guidelines on schizophrenia : Developmental process and selected recommendations].

18. Left prefrontal high-frequency rTMS may improve movement disorder in schizophrenia patients with predominant negative symptoms - A secondary analysis of a sham-controlled, randomized multicenter trial.

19. Effects of haloperidol and clozapine on synapse-related gene expression in specific brain regions of male rats.

20. The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia.

21. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care.

22. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

23. Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia: Results of the first-episode study within the German research network on schizophrenia.

24. Massive, previously undetected cancer metastasis revealed by application of a depot antipsychotic: a case report.

25. Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia.

26. [National and international schizophrenia guidelines. Update 2013 regarding recommendations about antipsychotic pharmacotherapy].

27. Predictors of symptomatic remission in first-episode psychosis outpatients treated with quetiapine: a naturalistic study.

28. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.

29. The diagnosis and treatment of bipolar disorder: recommendations from the current s3 guideline.

30. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.

33. Combination therapy in the treatment of schizophrenia.

34. Quetiapine improves sleep disturbance in acute bipolar disorder: a case series.

35. [Early detection and treatment of schizophrenia].

36. Achieving symptomatic remission in out-patients with schizophrenia--a naturalistic study with quetiapine.

37. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

38. Behavioural alterations in rats following neonatal hypoxia and effects of clozapine: implications for schizophrenia.

39. [Treatment of schizophrenia: what the family doctor should know].

40. [Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].

41. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.

42. Effects of antipsychotics on brain structure.

43. Clozapine alone versus clozapine and risperidone with refractory schizophrenia.

44. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.

45. [Longterm therapy of schizophrenia].

46. [Changes in brain structure caused by neuroleptic medication].

47. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.

48. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].

49. [The chances of new atypical substances].

50. Exploring Cariprazine's Potential in Late-Stage Schizophrenia Treatment.

Catalog

Books, media, physical & digital resources